BioSpace News Archive

AstraZeneca today announced positive progression-free survival (PFS) results for IMFINZI and tremelimumab, an anti-CTLA-4 antibody, when added to chemotherapy, from the Phase III POSEIDON trial in previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC).

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its third quarter 2019 financial results and provide a business update on Monday, November 4, 2019 prior to open of the U.S. financial markets.

Profound Medical Corp. (TSX:PRN; OTCQX:PRFMD) (“Profound” or the “Company”) today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has certified the Company’s common shares for listing on the Nasdaq Capital Market.

Welltower Inc. (NYSE: WELL) today announced results for the quarter ended September 30, 2019.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at The Society for Immunotherapy of Cancer (SITC) occurring November 6th-10th in National Harbor, Maryland.

Working together, the companies will use people plus technology to drive pharmacy benefit engagement and savings for employers and members

Kyocera Corporation (President: Hideo Tanimoto) announced that its smart, portable carbohydrate monitoring system was named the Grand Prix Runner-Up in the Smart X category at the 2019 CEATEC Awards.

Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced that it will report its fiscal 2020 first quarter financial results after the market closes on Thursday, November 7, 2019.

FDA Sets Prescription Drug User Fee Act (PDUFA) Goal Date of March 26, 2020

Arena Pharmaceuticals, Inc. announced that the first subject has been dosed in the Phase 2 ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe atopic dermatitis (AD).